TY - JOUR
T1 - Ten-year experience with nephrogenic systemic fibrosis
T2 - Case-control analysis of risk factors
AU - Bahrami, Simin
AU - Raman, Steven S.
AU - Sauk, Steven
AU - Salehmoghaddam, Saleh
AU - Villablanca, Juan Pablo
AU - Finn, J. Paul
AU - Lu, David S.K.
PY - 2009
Y1 - 2009
N2 - Objectives: To analyze all cases of nephrogenic systemic fibrosis (NSF) at our institution and to compare them with controls. Methods: After the institutional review board approval, 13 biopsy-proven NSF cases were identified. Ten cases had complete records and were compared in a case-control format with 10 age- and sex-matched, dialysis-dependent controls. Analyzed risk factors included single and cumulative gadolinium dose, medication and transplant history, and serum electrolytes at the time of gadolinium exposure. Results: There were 1.9% of dialysis-dependent, gadolinium-exposed patients who developed NSF. There was no difference in gadolinium dose, transplant history, or serum electrolytes. Seven of 10 cases and 3 of 10 controls were treated with erythropoietin (P = 0.13). At the time of NSF diagnosis, 7 of 10 cases were on immunosuppressive therapy. Two of 7 cases developed NSF only after immunosuppressive therapy wasinitiated. Two of 10 controls were on immunosuppressive therapy (P = 0.06). Conclusions: All cases of NSF occurred in dialysis-dependent, gadolinium-exposed patients. Associations between immunosuppressive and erythropoietin therapies and NSF need further investigation.
AB - Objectives: To analyze all cases of nephrogenic systemic fibrosis (NSF) at our institution and to compare them with controls. Methods: After the institutional review board approval, 13 biopsy-proven NSF cases were identified. Ten cases had complete records and were compared in a case-control format with 10 age- and sex-matched, dialysis-dependent controls. Analyzed risk factors included single and cumulative gadolinium dose, medication and transplant history, and serum electrolytes at the time of gadolinium exposure. Results: There were 1.9% of dialysis-dependent, gadolinium-exposed patients who developed NSF. There was no difference in gadolinium dose, transplant history, or serum electrolytes. Seven of 10 cases and 3 of 10 controls were treated with erythropoietin (P = 0.13). At the time of NSF diagnosis, 7 of 10 cases were on immunosuppressive therapy. Two of 7 cases developed NSF only after immunosuppressive therapy wasinitiated. Two of 10 controls were on immunosuppressive therapy (P = 0.06). Conclusions: All cases of NSF occurred in dialysis-dependent, gadolinium-exposed patients. Associations between immunosuppressive and erythropoietin therapies and NSF need further investigation.
KW - Dialysis
KW - Gadolinium
KW - MRI
KW - Nephrogenic systemic fibrosis
UR - http://www.scopus.com/inward/record.url?scp=73949113452&partnerID=8YFLogxK
U2 - 10.1097/RCT.0b013e31819d68ed
DO - 10.1097/RCT.0b013e31819d68ed
M3 - Article
C2 - 19940643
AN - SCOPUS:73949113452
SN - 0363-8715
VL - 33
SP - 819
EP - 823
JO - Journal of computer assisted tomography
JF - Journal of computer assisted tomography
IS - 6
ER -